Do recipients of kidneys from donors treated with streptokinase develop anti-streptokinase antibodies?
Streptokinase is used for preflush for non-heart-beating donors (NHBDs) in our center. The aim of this study was to evaluate whether the use of thrombolytic streptokinase results in the production of anti-streptokinase antibodies in the recipients after renal transplantation. Recipient sera taken prior to and at 1 and 6 months posttransplant were tested for the presence of antibodies to streptokinase using an enzyme-linked immunosorbent assay assay. No differences were detected between a group of 18 recipients who had kidneys from thrombolytic-treated NHBDs and a further group of 18 who received NHBD kidneys without such treatment.
Mi
H
H
Department of Renal and Liver Transplant, The Freeman Hospital, High Heaton, Newcastle Upon Tyne NE7 7DN, United Kingdom. D.Talbot@ncl.ac.uk
Gupta
A
A
Gok
M A
MA
Asher
J
J
Shenton
B K
BK
Stamp
S
S
Carter
V
V
Del Rio Martin
J
J
Soomro
N A
NA
Jaques
B C
BC
Manas
D M
DM
Talbot
D
D
D000906:Antibodies / Q000097:blood*; D000917:Antibody Formation; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006323:Heart Arrest; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D012189:Retrospective Studies; D013300:Streptokinase / Q000276:immunology* / Q000627:therapeutic use*; D014019:Tissue Donors
D000906:Antibodies; D005343:Fibrinolytic Agents; D013300:Streptokinase